Seattle, WA – May 15, 2026 – Azra AI, the leading end-to-end enterprise platform for incidental findings and oncology workflow automation, and RevealDx, the leader in AI tools for the characterization of lung nodules, today announced a new partnership.
This partnership builds upon Azra AI’s recent acquisition of Thynk health, which provides cancer screening and incidental findings management. Customers can now use one integrated solution to identify high-risk nodules, manage these nodules through diagnosis, and seamlessly connect to oncology workflow automation.
Recently cleared by the FDA, the RevealDx technology, marketed as RevealAI-Lung, characterizes incidental lung nodules by producing a score called the Malignancy Similarity Index (mSI™). mSI is intended to help radiologists make more informed follow-up recommendations to assist in cancer diagnosis. The company has validated the software on over 1,500 patients from a variety of cohorts, and RevealAI-Lung is now reimbursable by Medicare using codes 0721T and 0722T.
“This partnership strengthens our enterprise-wide intelligence platform,” said John Marshall, CEO of Azra AI. “The integration of the mSI score into the clinical workflow empowers providers to diagnose patients earlier while increasing clinical efficiency. We are excited to deliver this new technology to our customers because not only are we detecting lung cancer earlier with RevealDX, but once identified Azra’s oncology platform will then coordinate the patient’s care all the way through survivorship.”
“When vendors partner, patients and providers can benefit, and that is certainly the case here,” said Chris Wood, CEO of RevealDx. “We are proud of the fact that Azra AI chose to integrate mSI into their clinical workflows, and introduce RevealAI-Lung to their installed base. Just producing a malignancy risk score is not sufficient. It needs to be integrated into platforms built for the full continuum, which is exactly what Azra AI provides.”
